Your browser doesn't support javascript.
loading
Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.
Goel, Sanjay; Viteri, Santiago; Morán, Teresa; Coronado, Cinthya; Dios, Jorge Luis Iglesias; Miguel-Lillo, Bernardo; Fernández-García, Eva M; Rosell, Rafael.
Affiliation
  • Goel S; Montefiore Medical Center, 1695 Eastchester Road, Bronx, NY, 10461, USA. sgoel@montefiore.org.
  • Viteri S; Instituto Universitario Dexeus, Barcelona, Spain.
  • Morán T; Catalan Institute of Oncology, Hospital Germans Trias I Pujol, Badalona, Spain.
  • Coronado C; Pharma Mar, S.A., Madrid, Spain.
  • Dios JL; Pharma Mar, S.A., Madrid, Spain.
  • Miguel-Lillo B; Pharma Mar, S.A., Madrid, Spain.
  • Fernández-García EM; Pharma Mar, S.A., Madrid, Spain.
  • Rosell R; Catalan Institute of Oncology, Hospital Germans Trias I Pujol, Badalona, Spain.
Invest New Drugs ; 34(1): 75-83, 2016 Feb.
Article in En | MEDLINE | ID: mdl-26627080
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2016 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2016 Type: Article Affiliation country: United States